Skip to main content
Premium Trial:

Request an Annual Quote

EpiVax Wins $1M NIH SBIR Grant to Screen Genomes for Smallpox Vaccine

NEW YORK, Dec. 20 (GenomeWeb News) - EpiVax has won a $993,771 Phase I SBIR grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop a smallpox vaccine, its second SBIR grant this year, the company said today.

 

EpiVax, a provider of protein and genome analysis services and vaccine candidates that is based in Providence, RI, plans to use the award to screen the genomes of variola, which causes smallpox, and vaccinia, which causes cowpox, for common epitopes that drive immunity.

 

In September, EpiVax received an $859,773 biodefense grant to develop a vaccine for Tularemia.

The Scan

Plan Rebuffed

The Associated Press reports China has rejected the World Health Organization's proposal to include the lab-leak theory in the next phase of its investigation into the origins of SARS-CoV-2.

Opossum Change

Researchers from Riken have used CRISPR to edit marsupial genomes, as Technology Review reports.

In the Ice

Cosmos magazine reports that researchers have uncovered more than two dozen ancient viruses in a Tibetan glacier.

Nature Papers Present Method to Uncover Differential RNA Modifications, Neutrophils in Innate Immune Response

In Nature this week: computational approach to identifying differential RNA modifications, and more.